Neuren partner Acadia bags FDA go-ahead for new DAYBUE STIX powder for Rett Syndrome
The new powder formulation gives children and adults living with Rett syndrome greater flexibility and choice in dose volume and taste
The new powder formulation gives children and adults living with Rett syndrome greater flexibility and choice in dose volume and taste
Alphyn is developing Zabalafin Hydrogel as the first therapy to simultaneously tackle the interconnected drivers of AD
The state-of-the-art facility is a 350-bedded, multi-specialty tertiary care hospital
Dr Srivastava was selected by an expert jury in recognition of her sustained contributions to renewable chemicals, industrial biotechnology and bioprocess innovation
The drug is currently being evaluated in two fully recruited global Phase 3 studies for progressive and tophaceous gout, with results expected in 2026.
The study also showed a clear dose-dependent trend, with the 75 mg QD group outperforming the 50 mg QD cohort
More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
Her journey includes leading HR for large and diverse teams across sales, marketing, corporate functions, and R&D
In her previous roles, Menon led significant digital transformation efforts, implementing predictive analytics, automation
Subscribe To Our Newsletter & Stay Updated